PI3K and mTOR inhibitor
Catalog No. F17-900
| Catalog No. | Pack Size | Price (USD) | |
|---|---|---|---|
| F17-900-10 | 10 mg | $60 | |
| F17-900-50 | 50 mg | $180 | |
| F17-900-BULK | BULK | Contact Us |
Overview:
A dual PI3K and mTOR kinase inhibitor (1). It inhibits VEGF-induced proliferation and angiogenesis (2). Reverses lapatinib resistance (3). It induces G1 arrest and reduces cyclin D1 expression in melanoma cells with negligible apoptosis (4). Inhibits the growth of cancer cells with activating PI3K mutations (5). Active in vivo.
References:
1. SM Maira et al. Mol. Cancer Ther. 2008 7:1851
2. CR Schnell et al. Cancer Res. 2008 68:6598
3. PJ Eichhorn et al. Cancer Res. 2008 68:9221
4. R Marone et al. Mol. Cancer Res. 2009 7:601
5. V Serra et al. Cancer Res. 2008 68:8022
CAS Registry Number:
915019-65-7
Molecular Formula:
C30H23N5O
Appearance:
White to off-white powder
Melting Point:
285-287oC
Molecular Weight:
469.5
Purity:
>98% (TLC); NMR (Conforms)
Solubilization:
May be dissolved in DMSO (1 mg/ml, warm); or DMF (10 mg/ml, warm to 75oC)
Aliases:
2-Methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c] quinolin-1-yl] phenyl} propanenitrile
Storage and Stability:
Store desiccated as supplied at -20oC for up to 2 years. Store solutions at -20oC for up to 1 month.
Molecular Structure:
|
There are no related publications available for this product.
AKT/PKB Pathway, Angiogenesis, Apoptosis/Autophagy, Cancer, Cardiovascular Disease, Inflammation, Invasion/Metastasis, Lipid Kinases, Metabolic Disorder, Neurobiology, NfkB Pathway, WNT Signaling
STAY CONNECTED
Fax: 1-604-232-4601
Toll Free: 1-866-954-6273
info@signalchem.com